[{"notes_id":"1_893","category":"8","subcategory":"0","title":"Dopamine receptor agonists","body":"Indications<br \/><ul><li>Parkinson's disease<\/li><li>prolactinoma\/galactorrhoea<\/li><li>cyclical breast disease<\/li><li>acromegaly<\/li><\/ul><br \/>Currently accepted practice in the management of patients with Parkinson's disease is to delay treatment until the onset of disabling symptoms and then to introduce a dopamine receptor agonist. If the patient is elderly, L-dopa is sometimes used as an initial treatment<br \/><br \/>Overview<br \/><ul><li>e.g. bromocriptine, ropinirole, cabergoline, apomorphine<\/li><li>ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide*) have been associated with <span class=\"concept\" data-cid=\"6278\">pulmonary, retroperitoneal and cardiac fibrosis<\/span>. The Committee on Safety of Medicines advice that an ESR, creatinine and chest x-ray should be obtained prior to treatment and patients should be closely monitored<\/li><\/ul><br \/>Adverse effects<br \/><ul><li>nausea\/vomiting<\/li><li>postural hypotension<\/li><li>hallucinations<\/li><li>daytime somnolence<\/li><\/ul><br \/>*pergolide was withdrawn from the US market in March 2007 due to concern regarding increased incidence of valvular dysfunction","notes_hash":"21d5af279fe0c9668fd1a17d24eb62d4","knowledge_graph_node_id_link":0,"links":"","media":"","concepts_for_notes":{"6278":{"concept_text":"Bromocriptine may cause pulmonary, retroperitoneal and cardiac fibrosis","concept_percentile":"7"}},"category_name":"Pharmacology and therapeutics","subcategory_name":"","comment_count":3},"",[]]